文献速递炎症性肠病

晚期联合治疗对难治性炎症性肠病或合并免疫介导疾病或肠外表现患者的有效性与安全性:加拿大全国多中心研究

Effectiveness and Safety of Advanced Combination Treatment in Patients With Refractory Inflammatory Bowel Disease or Concomitant Immune-Mediated Disease or Extraintestinal Manifestations: A Multicenter Canadian Study.
PubMed 文献 · Am J Gastroenterol · 2025-06-05

该多中心研究纳入9个加拿大中心的105例成人炎症性肠病(IBD)患者,接受两种生物制剂、生物制剂联合口服小分子或两种小分子药物组成的晚期联合治疗(ACT)。12个月时临床应答和缓解率分别为60.0%和29.5%,内镜应答和缓解率分别为32.4%和28.6%。肛周病变与临床缓解(HR=0.33)和内镜应答(HR=0.42)降低相关,严重不良事件和感染发生率分别为12.4%和7.6%。

要点

  • ACT在难治性IBD或合并免疫介导疾病/肠外表现患者中可达到临床和内镜结局,安全性良好。
  • 肛周病变与临床缓解(HR=0.33,95%CI:0.17-0.65,P=0.001)和内镜应答(HR=0.42,95%CI:0.12-0.50,P=0.001)降低相关。
  • 12个月时临床应答率60.0%、临床缓解率29.5%、内镜应答率32.4%、内镜缓解率28.6%。

核心结论

  • ACT在难治性IBD或合并免疫介导疾病/肠外表现患者中可有效达到临床和内镜结局,且安全性良好。

研究设计与样本

  • 加拿大9个中心的多中心研究,纳入105例成人IBD患者(76例克罗恩病,29例溃疡性结肠炎),中位年龄35岁(IQR 35.4-40.8)。
  • ACT定义为两种生物制剂、生物制剂联合口服小分子或两种小分子药物联合治疗。
  • ACT指征包括难治性IBD、未控制的免疫介导疾病和未控制的肠外表现。

主要发现

  • 12个月时临床应答累积率为60.0%,内镜应答累积率为32.4%,临床缓解率为29.5%,内镜缓解率为28.6%。
  • 肛周病变与临床缓解降低相关(HR=0.33,95%CI:0.17-0.65,P=0.001),与内镜应答降低相关(HR=0.42,95%CI:0.12-0.50,P=0.001)。
  • 病程较长(HR=0.96,95%CI:0.92-0.99,P=0.035)和基线使用激素(HR=0.39,P=0.006)与临床缓解降低相关。
  • 严重不良事件发生率为12.4%,感染发生率为7.6%。

关键数值与推荐

  • 基线时39%有肛周病变,58%至少失败过3种晚期治疗,40%有既往手术史。
  • ACT的主要原因为难治性IBD(63.8%),97.1%的病例采用添加(add-on)策略。
  • 最常见的联合方案为抗肿瘤坏死因子+抗整合素。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Owing to the therapeutic ceiling associated with inflammatory bowel disease (IBD) therapies, some patients may require 2 advanced therapeutic agents, known as advanced combination treatment (ACT) to control disease or treat associated extraintestinal manifestations (EIMs). METHODS: We included adult patients with IBD from 9 Canadian centers treated with either 2 biological therapies, a biological plus an oral small molecule, or 2 small molecules. Indications for ACT were the following: (i) refractory IBD, (ii) uncontrolled immune mediated diseases, and (iii) uncontrolled EIMs. Primary outcomes were cumulative rates of clinical and endoscopic response and remission at 6 and 12 months. Secondary outcomes included serious adverse events and infections. Cox-proportional hazard analyses identified independent predictors of treatment effectiveness. RESULTS: We included 105 IBD patients (76 Crohn's disease, 29 ulcerative colitis) with median age 35 years (Interquartile Range 35.4-40.8). At baseline, 39% had perianal involvement, 58% had failed at least 3 advanced therapies, and 40% had previous surgery. The primary reason for ACT was refractory IBD (63.8%), with the add-on approach used in 97.1% cases. The most frequent combination was antitumor necrosis factor + anti-integrin. At 12 months, cumulative rates of clinical and endoscopic response were 60.0% and 32.4%, respectively, and remission rates were 29.5% and 28.6%. Perianal disease was associated with reduced clinical remission (hazard ratio [HR] = 0.33, 95% confidence interval [CI]: 0.17-0.65, P = 0.001) and endoscopic response (HR = 0.42, 95% CI: 0.12-0.50, P = 0.001). Longer disease duration (HR = 0.96, 95% CI: 0.92-0.99, P = 0.035) and baseline steroid use (HR = 0.39, P = 0.006) was associated with reduced clinical remission. Serious adverse events and infections occurred in 12.4% and 7.6% of patients, respectively. DISCUSSION: ACT was effective in achieving clinical and endoscopic outcomes in patients with refractory IBD or concomitant immune-mediated diseases/EIMs, with favorable safety profile.

来源:Am J Gastroenterol,查看原文。版权归原作者所有。

引用

  1. Solitano V, Ogunsakin RE, Yuan Y, et al. Effectiveness and Safety of Advanced Combination Treatment in Patients With Refractory Inflammatory Bowel Disease or Concomitant Immune-Mediated Disease or Extraintestinal Manifestations: A Multicenter Canadian Study. Am J Gastroenterol. 2025. PMID: 40471825. doi:10.14309/ajg.0000000000003573

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。